Dg Capital Management, LLC United Therapeutics Corp Transaction History

Dg Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$211.82 - $248.24 $7.7 Million - $9.02 Million	36,333 Added 219.14%	52,913 $12 Million
Q2 2023 Aug 11, 2023	SELL	$205.19 - $232.99 $7.53 Million - $8.55 Million	-36,700 Reduced 68.88%	16,580 $3.66 Million
Q1 2023 May 11, 2023	BUY	$212.99 - $276.17 $11.3 Million - $14.7 Million	53,280 New	53,280 $11.9 Million
Q2 2022 Aug 12, 2022	SELL	$174.81 - $241.14 $19 Million - $26.3 Million	-108,955 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$166.16 - $213.96 $4.7 Million - $6.05 Million	-28,299 Reduced 20.62%	108,955 $19.5 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $1.33 Million - $1.56 Million	7,223 Added 5.55%	137,254 $29.7 Million
Q3 2021 Nov 12, 2021	SELL	$179.86 - $214.88 $1.85 Million - $2.21 Million	-10,268 Reduced 7.32%	130,031 $24 Million
Q2 2021 Aug 12, 2021	BUY	$170.47 - $211.93 $141,149 - $175,478	828 Added 0.59%	140,299 $25.2 Million
Q1 2021 May 13, 2021	BUY	$153.94 - $174.85 $7.09 Million - $8.05 Million	46,055 Added 49.3%	139,471 $23.3 Million
Q4 2020 Feb 12, 2021	BUY	$101.87 - $151.79 $9.52 Million - $14.2 Million	93,416 New	93,416 $14.2 Million

673

42.2M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Dg Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Dg Capital Management, LLC with notifications on news.